We report a rare case of a patient with prosthetic valve endocarditis (PVE) requiring implantation of a total artificial heart (TAH) as a bridge to heart transplantation. Gemella haemolysans, an unusual cause of PVE, was identified as the organism responsible only by 16s rRNA polymerase chain reaction analysis of surgical tissue samples. We also describe one of the first uses of combined TAH and veno-venous extracorporeal membrane oxygenation therapy in the setting of severe respiratory and cardiac failure. Implantation of a TAH may be considered in situations where more traditional reconstructive methods are not feasible. ASAIO Journal 2014; 60:479-481.
Prosthetic valve endocarditis (PVE) is a serious disease with significant mortality. 1 Treatment requires prolonged antimicrobial therapy, usually with a combination of multiple agents. Surgical therapy is also frequently necessary. Although implantation of a total artificial heart (TAH) is typically used as a bridge to heart transplantation in patients with severe biventricular heart failure, 2 implantation of a TAH as a treatment for severe PVE has rarely been reported. 3 We describe a patient with severe culture-negative PVE due to Gemella haemolysans who underwent TAH implantation, initially in conjunction with veno-venous extracorporeal membrane oxygenation (VV-ECMO), as a bridge to successful heart transplant.
Case
A 40-year-old woman had congenital aortic coarctation, repaired at age 4 years, and a bicuspid aortic valve with subsequent symptomatic aortic stenosis requiring bioprosthetic aortic valve replacement and root enlargement at age 32 years. Five months before admission, progressive shortness of breath, lower extremity edema, fevers with temperatures to 39°C, myalgias, and night sweats developed. She was treated empirically with oseltamivir, doxycycline, and eventually with clarithromycin and a short course of prednisone for possible bronchitis, without improvement. At a referring facility, a transthoracic echocardiogram was suggestive of endocarditis with a paravalvular aortic root abscess. She was treated with vancomycin and ceftriaxone, but 2 days later pulmonary edema, an elevated troponin I to 74 ng/ml (normal < 0.4), and an elevated white blood cell count to 21,000 per cubic millimeter developed. She was transferred to our institution where a repeat transthoracic echocardiogram (Figure 1) showed new systolic dysfunction, regional akinesis, and an ejection fraction of 36% (previously normal) with possible left ventricular thrombus. There was a large abscess around the bioprosthetic aortic valve abutting the coronary ostia with dehiscence of the aortic root from the aortic annulus. Gentamicin and rifampin were added to her prior antibiotics.
After hemodynamic stabilization, she was taken to the operating room for exploration and definitive therapy. She was found to have an infection involving both coronary ostia, a root abscess extending into the right atrium, and insufficient tissue to perform a root reconstruction. She therefore underwent extensive debridement mandating reconstruction with a TAH.
Once complete, she suffered from profound respiratory failure with poor oxygenation and high peak airway pressures consistent with a systemic inflammatory response. With an arterial partial pressure of oxygen of 46 mm Hg, an arterial partial pressure of carbon dioxide of 78 mm Hg, and a pH of 7.14 on aggressive ventilator settings, she was placed on VV-ECMO for support. Cannulation was accomplished via the common femoral vein into the intrahepatic vena cava and return directly into the right atrium with a cannula placed parallel to the right-sided inflow (tricuspid) valve. VV-ECMO flows were brought up to around 3 L/min, which quickly stabilized gas exchange.
Over the ensuing 4 days, her respiratory function improved such that VV-ECMO could be weaned. All blood and tissue cultures from her aortic and right atrial abscess remained negative. However, 16s rRNA polymerase chain reaction (PCR) identified G. haemolysans in all tissue specimens. Pathology of her explanted heart showed both ischemic and embolic infarcts of varying ages (i.e., several weeks).
Antibiotics were changed to ampicillin and gentamicin, which continued for another 4 weeks, and she was maintained on suppressive oral amoxicillin. She underwent successful heart transplantation 6 months later and continues to do well 7 months afterward.
Discussion
Prosthetic valve endocarditis involves between 1% and 6% of prosthetic valves and may account for up to one-third of all cases of infective endocarditis (IE). 1, 4 PVE continues to be a serious disease with high mortality. Therapy requires prolonged use of intravenous antimicrobial agents, usually a combination of agents. 5 Whether surgery provides additional benefit in routine cases of PVE is not clear. 6, 7 However, in certain individuals, urgent valve surgery is critical. Indications for surgery include severe heart failure, myocardial abscess, valve dehiscence, new conduction disturbance, or large vegetations. 8 Our patient met several of these criteria.
Due to displacement of the aortic root from the base of the heart leading to distortion of the coronary arteries, large myocardial infarction and right ventricular dysfunction, aortic root reconstruction was not possible. 9 An intraoperative judgment that a complex reconstruction would not be tolerated resulted in an unconventional use of the TAH. Total artificial heart has been used to provide mechanical circulatory support in patients with severe biventricular heart failure. In recent reports, 61%-68% of patients with a SynCardia TAH survived to transplant, with a mean time until transplant of 87-97 days. 3, 10 The use of a TAH in the management of severe IE has only rarely been described. 3 The combined use of TAH and VV-ECMO has been previously reported. 11 Because of the presence of the mechanical valves, technical considerations for cannulation are imperative. In this case, the ECMO inflow was placed in the IVC, and the outflow was placed parallel to the rightsided inflow valve directly in the right atrium. This arrangement resulted in excellent support with no ECMO flow limitation and without concern for valvular interference by the cannulae.
The most common organisms associated with PVE include coagulase-negative staphylocci, Staphylococcus aureus, enterococci, and Streptococcus viridans group organisms. 4 G. haemolysans is a gram-positive coccus, often found as a commensal organism in the upper respiratory, gastrointestinal, and genitourinary tract, and occasionally causes both localized and disseminated infections. It is an uncommon cause of endocarditis, with only about 20 cases reported in the literature and rarely associated with PVE. 12 Most documented cases of G. haemolysans endocarditis have been associated with previous valvular damage in the setting of poor dentition or dental manipulation, which was not the situation with this patient. Antimicrobial therapy for G. haemolysans IE would typically include penicillin or ampicillin in combination with gentamicin. 5, 13 Our patient received 4 weeks of ampicillin and gentamicin after TAH implantation. Oral amoxicillin was continued as suppressive therapy until after heart transplantation given the possibility that the new artificial device had become infected at the time of implantation.
Culture-negative endocarditis occurs in approximately 5%-15% of IE. 14, 15 Molecular methods using 16s rRNA PCR may be extremely helpful in identifying a causative agent using valve tissue at the time of surgery. 16 This technique may find organisms that are difficult to grow or whose growth has been suppressed by prior antibiotic treatment, such as the G. haemolysans seen here. 17 Although susceptibility testing by PCR is not presently available, identification of the etiologic agent may be enough to allow revision of the antimicrobial regimen, as was seen in this case. We recommend that all patients with culture-negative IE who undergo valve replacement have tissue samples examined using this method.
In summary, we describe a rare case in which TAH was used as bridge to transplantation for severe culture-negative PVE. In addition, we describe one of the first uses of combined TAH and VV-ECMO for both cardiac and respiratory support. We emphasize the utility of 16s rRNA PCR to help identify the causative agent when cultures are negative. Implantation of a TAH may be considered in situations where more traditional reconstructive methods are not feasible anatomically or physiologically. 
